CN112616775A - Method for establishing hepatic fibrosis of healthy SD male rat by adopting compound factor method - Google Patents
Method for establishing hepatic fibrosis of healthy SD male rat by adopting compound factor method Download PDFInfo
- Publication number
- CN112616775A CN112616775A CN202011606455.XA CN202011606455A CN112616775A CN 112616775 A CN112616775 A CN 112616775A CN 202011606455 A CN202011606455 A CN 202011606455A CN 112616775 A CN112616775 A CN 112616775A
- Authority
- CN
- China
- Prior art keywords
- healthy
- establishing
- rat
- feeding
- steps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 241000700159 Rattus Species 0.000 claims abstract description 48
- 210000000130 stem cell Anatomy 0.000 claims abstract description 29
- 210000004369 blood Anatomy 0.000 claims abstract description 26
- 239000008280 blood Substances 0.000 claims abstract description 26
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 238000012258 culturing Methods 0.000 claims abstract description 14
- 239000013543 active substance Substances 0.000 claims abstract description 13
- MDBGGTQNNUOQRC-UHFFFAOYSA-N Allidochlor Chemical compound ClCC(=O)N(CC=C)CC=C MDBGGTQNNUOQRC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000242678 Schistosoma Species 0.000 claims abstract description 6
- 230000037396 body weight Effects 0.000 claims abstract description 6
- 210000000601 blood cell Anatomy 0.000 claims abstract description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 22
- 210000005228 liver tissue Anatomy 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 18
- 230000005284 excitation Effects 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000010186 staining Methods 0.000 claims description 9
- 239000012894 fetal calf serum Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 108010019160 Pancreatin Proteins 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 229940055695 pancreatin Drugs 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 5
- 230000037213 diet Effects 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 239000003651 drinking water Substances 0.000 claims description 3
- 235000020188 drinking water Nutrition 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 238000000695 excitation spectrum Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 238000001215 fluorescent labelling Methods 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 235000012631 food intake Nutrition 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 230000006996 mental state Effects 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 239000008174 sterile solution Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract description 11
- 208000037273 Pathologic Processes Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000009054 pathological process Effects 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract description 2
- 238000003975 animal breeding Methods 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 9
- 230000006698 induction Effects 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000019137 high fructose diet Nutrition 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of medical animal breeding, and discloses a method for establishing hepatic fibrosis of a healthy SD male rat by adopting a compound factor method, which comprises the following steps: s1: culturing the blood stem cells; s2: preparing stem cell active matters; according to the following steps: 1: 1, mixing A, B with blood cells of schistosome to obtain active substance of blood stem cells; s3: feeding and culturing adult SD male rats; s4: feeding for 1 week, measuring body weight of the rat, feeding high-fat CDAA feed, and injecting blood stem cell active matter; the compound factor is formed by mixing the blood stem cells, the stem cell active matter and the schistosome and is injected into a healthy SD male rat, the animal model prepared by the rat conforms to the pathological process of conversion from NASH to HCC, the operation is easy, the time consumption is short, the stability and the effectiveness are realized, the modeling and the technical support are provided for developing and developing a new medicine for treating the non-alcoholic steatohepatitis, and the compound factor has great economic and social benefits.
Description
Technical Field
The invention relates to the technical field of medical animal cultivation, in particular to a method for establishing hepatic fibrosis of healthy SD male rats by adopting a compound factor method.
Background
Hepatic fibrosis is a pathophysiological process, which refers to abnormal proliferation of connective tissue in the liver caused by various pathogenic factors. Any liver injury has liver fibrosis in the process of liver repair and healing, and if the injury factor cannot be removed for a long time, the fibrosis process can be continuously developed into liver cirrhosis for a long time. It is therefore not an independent disease; a composite factor is a collective term for a plurality of factors related to functions or sources.
The model animals currently used for researching NASH, hepatic fibrosis, liver cirrhosis and HCC mainly have chemical poison induction, physical injury, pathological diet, gene knockout and the like. These techniques all suffer from the following problems:
(1) the induction of chemical poison is to inject DEN or carbon tetrachloride (CCl4) into rats or mice through digestive tract and abdominal cavity to induce liver cells to be acutely or chronically damaged, so that liver fibrosis, liver cirrhosis and liver cancer are formed, although liver cancer can be induced, the natural evolution process of human from simple fatty liver, NASH to HCC cannot be completely simulated, and the basic model parameters required by NASH-HCC research and new drug development are not provided.
(2) Physical injury modeling is to ligate the hepatic bile duct of rat or mouse to cause mechanical intrahepatic cholestasis, which leads to progressive liver injury, hepatic fibrosis, cirrhosis and liver cancer formation. However, the modeling is usually used for basic research and drug development of hepatic fibrosis and liver cirrhosis, and is still not suitable for basic model parameters required by NASH-HCC research and new drug development.
(3) Pathologic diet induction modeling is the induction of fatty liver, NASH and HCC formation by feeding rats or mice on a high-fat, choline-deficient, high-fructose diet. Although the model is close to the pathological process of human NASH-HCC, the period is long, HCC does not appear in all animals finally, the observation time is about more than 24 months, and the model is not beneficial to experimental research.
(4) The gene knockout induction of liver cancer modeling is realized by knocking out the combination of cancer suppressor genes. The modeling can form fatty liver, hepatic fibrosis, NASH and HCC, but the gene knockout method is expensive in cost, difficult to operate and not beneficial to smooth experiment.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a method for establishing hepatic fibrosis of a healthy SD male rat by adopting a compound factor method, which has the advantages of easy operation and short time consumption and solves the problem of difficult operation.
(II) technical scheme
In order to achieve the purpose, the invention provides the following technical scheme: a method for establishing hepatic fibrosis of healthy SD male rats by adopting a compound factor method comprises the following steps:
s1: culture of blood Stem cells
Adding PBS into intestinal blood for dilution, adding 10ml of lymphocyte separation liquid into a 50ml centrifuge tube, slowly adding the diluted intestinal blood, slowly sucking out the white cloudy lymphocyte layer in the middle of layering, adding PBS, centrifuging for 5 minutes, removing supernatant after centrifuging, adding fetal calf serum again, mixing uniformly, and repeatedly centrifuging once; discarding the supernatant, adding culture medium, mixing, and standing at 100cm2Culturing in the culture bottle;
s2: preparation of Stem cell active
Taking cultured stem cells for digestion and counting, washing fetal calf serum for 3 times, dissolving in 30ml of physiological saline, and ultrasonically breaking the cells; dissolving out intracellular protein and nutrients, centrifuging for 10 min, collecting supernatant, removing cell debris, concentrating with ultrafiltration membrane, removing immunoglobulin, collecting filtrate, filtering with filter membrane to obtain sterile solution with concentration of 200 μ g/ml, and storing at 4 deg.C to obtain solution A;
measuring the pH value of the upper layer culture solution of 30ml when the pH value of the culture medium for culturing the cells is 5.5, filtering by using a filter membrane to concentrate the volume of the upper layer culture solution to about 5ml, taking out the upper layer culture solution, adding 5ml of normal saline, and fixing the volume to 10 ml; filtering with 0.22 μm filter membrane to make it sterile, measuring protein concentration, determining concentration to be 200 μ g/ml, and storing at 4 deg.C to obtain solution B;
according to the following steps: 1: 1, mixing A, B with blood cells of schistosome to obtain active substance of blood stem cells;
s3: feeding and culturing adult SD male rats;
s4: feeding the rats after the weight measurement for 1 week, feeding high-fat CDAA feed, injecting blood stem cell active substances, continuously culturing for 8 weeks, wherein the injection of the blood stem cell active substances is carried out for 2 days in one week, and the common drinking water is carried out for the other 5 days;
s5: observing the mental state and hair condition of the rat every day during feeding, measuring the food intake and water intake, measuring the body weight of the rat every week, starting from the first feeding of high-fat CDAA diet and injection of blood stem cell active substances, continuously feeding for 8 weeks, and obtaining the rat with hepatic fibrosis.
Preferably, S3 further comprises subjecting SD male rats to 25-30 deg.C room temperature and 55% -65% humidity cage, adaptively feeding for 1 week in 12 hr light/dark cycle, and measuring body weight of the rats.
Preferably, the high fat CDAA feed in S4, wherein, by weight: fat 32%, carbohydrate 55%, protein 13%, choline 0; the carbohydrate is starch, dextrin, sugar, and protein as amino acid premix, the fat is oleum Maydis and hydrogenated vegetable oil, and the calorie is 4.3 kcal/g.
Preferably, the step S1 further includes:
s11: when the cells grow to 80-90% of the bottom of the culture bottle, sucking out the culture medium, adding PBS for washing, sucking out PBS, adding pancreatin, adding alpha-MEM culture medium containing 20% fetal calf serum, neutralizing the pancreatin, sucking out the neutralization solution, putting into a centrifuge tube, adding PBS, centrifuging for 5 minutes, removing the supernatant after centrifugation, adding PBS, mixing uniformly, re-centrifuging once, counting the cells, adding 2X 105 cells into each bottle, and placing into a culture bottle of 100cm2 for culture.
Preferably, the method further comprises the step of S5:
the liver puncture tissue specimen of the SD male rat is directly provided with collagen specificity excitation spectrum to directly excite isolated liver tissue without any chemical special staining, and the inherent fluorescence characteristics of the liver tissue are observed by using a special fluorescence excitation block system of a fluorescence microscope to diagnose the liver fibrosis degree.
Preferably, it is characterized in that: the excitation light wavelength of the special fluorescence excitation block in S5 is distributed in the lower range of 300nm-460nm, and the liver tissue section for liver fibrosis diagnosis is a liver tissue section without any staining.
Preferably, it is characterized in that: the liver fibrosis diagnosis system aims at liver tissue sections including frozen sections and paraffin-embedded sections, and the inherent fluorescence of the liver tissue is generated after an optical filter in a lower wavelength range of 300nm-460nm or the excitation light of other corresponding light sources is excited without any chemical staining or fluorescence labeling.
Preferably, the liver fibrosis diagnosis system of S5 comprises any means for determining the degree of liver fibrosis based on the inherent fluorescence characteristics of the liver tissue specimen and the wavelength range of 300nm-460 nm.
(III) advantageous effects
Compared with the prior art, the invention provides a method for establishing hepatic fibrosis of healthy SD male rats by adopting a compound factor method, which has the following beneficial effects:
the method for establishing the hepatic fibrosis of the healthy SD male rat by adopting the compound factor method comprises the steps of mixing the blood stem cells, the stem cell active matter and the schistosome to form the compound factor, injecting the compound factor into the healthy SD male rat, wherein an animal model prepared by the rat accords with the pathological process of conversion from NASH to HCC, is easy to operate, short in time, stable and effective, provides modeling and technical support for developing and developing a new medicine for treating nonalcoholic steatohepatitis, and has huge economic and social benefits.
Drawings
FIG. 1 is a schematic view of the structure of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1, a method for establishing hepatic fibrosis in healthy SD male rats by using a complex factor method comprises the following steps:
s1: culture of blood Stem cells
Diluting intestinal blood with PBS, adding 10ml lymphocyte separation solution into 50ml centrifuge tube, slowly adding diluted intestinal blood, slowly sucking out white nebulous lymphocyte layer in middle of layer, addingCentrifuging the PBS for 5 minutes, removing the supernatant after centrifugation, adding fetal bovine serum again, mixing uniformly, and repeatedly centrifuging once; discarding the supernatant, adding culture medium, mixing, and standing at 100cm2Culturing in the culture bottle;
s2: preparation of Stem cell active
Taking cultured stem cells for digestion and counting, washing fetal calf serum for 3 times, dissolving in 30ml of physiological saline, and ultrasonically breaking the cells; dissolving out intracellular protein and nutrients, centrifuging for 10 min, collecting supernatant, removing cell debris, concentrating with ultrafiltration membrane, removing immunoglobulin, collecting filtrate, filtering with filter membrane to obtain sterile solution with concentration of 200 μ g/ml, and storing at 4 deg.C to obtain solution A;
measuring the pH value of the upper layer culture solution of 30ml when the pH value of the culture medium for culturing the cells is 5.5, filtering by using a filter membrane to concentrate the volume of the upper layer culture solution to about 5ml, taking out the upper layer culture solution, adding 5ml of normal saline, and fixing the volume to 10 ml; filtering with 0.22 μm filter membrane to make it sterile, measuring protein concentration, determining concentration to be 200 μ g/ml, and storing at 4 deg.C to obtain solution B;
according to the following steps: 1: 1, mixing A, B with blood cells of schistosome to obtain active substance of blood stem cells;
s3: feeding and culturing adult SD male rats;
s4: feeding the rats after the weight measurement for 1 week, feeding high-fat CDAA feed, injecting blood stem cell active substances, continuously culturing for 8 weeks, wherein the injection of the blood stem cell active substances is carried out for 2 days in one week, and the common drinking water is carried out for the other 5 days;
s5: observing the mental state and hair condition of the rat every day during feeding, measuring the food intake and water intake, measuring the body weight of the rat every week, starting from the first feeding of high-fat CDAA diet and injection of blood stem cell active substances, continuously feeding for 8 weeks, and obtaining the rat with hepatic fibrosis.
In this example, S3 further comprises measuring the body weight of SD male rats by placing them in cages at room temperature of 25-30 deg.C and humidity of 55% -65%, and adaptively feeding them for 1 week in 12-hour light/dark cycle.
In this embodiment, specifically, the high-fat CDAA feed in S4, wherein by weight: fat 32%, carbohydrate 55%, protein 13%, choline 0; the carbohydrate is starch, dextrin, sugar, and protein as amino acid premix, the fat is oleum Maydis and hydrogenated vegetable oil, and the calorie is 4.3 kcal/g.
In this embodiment, specifically, the step S1 further includes the following steps:
s11: when the cells grow to 80-90% of the bottom of the culture bottle, sucking out the culture medium, adding PBS for washing, sucking out PBS, adding pancreatin, adding alpha-MEM culture medium containing 20% fetal calf serum, neutralizing the pancreatin, sucking out the neutralization solution, putting into a centrifuge tube, adding PBS, centrifuging for 5 minutes, removing the supernatant after centrifugation, adding PBS, mixing uniformly, re-centrifuging once, counting the cells, adding 2X 105 cells into each bottle, and placing into a culture bottle of 100cm2 for culture.
In this embodiment, specifically, the method further includes S5:
the liver puncture tissue specimen of the SD male rat is directly provided with collagen specificity excitation spectrum to directly excite isolated liver tissue without any chemical special staining, and the inherent fluorescence characteristics of the liver tissue are observed by using a special fluorescence excitation block system of a fluorescence microscope to diagnose the liver fibrosis degree.
In this embodiment, specifically, the following features are provided: the excitation light wavelength of the special fluorescence excitation block in S5 is distributed in the lower range of 300nm-460nm, and the liver tissue section for liver fibrosis diagnosis is a liver tissue section without any staining.
In this embodiment, specifically, the following features are provided: the liver fibrosis diagnosis system aims at liver tissue sections including frozen sections and paraffin-embedded sections, and the inherent fluorescence of the liver tissue is generated after an optical filter in a lower wavelength range of 300nm-460nm or the excitation light of other corresponding light sources is excited without any chemical staining or fluorescence labeling.
In this embodiment, the liver fibrosis diagnosis system in S5 includes any means for determining the degree of liver fibrosis based on the inherent fluorescence characteristics of the liver tissue specimen and the wavelength range between 300nm and 460 nm.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (8)
1. A method for establishing hepatic fibrosis of healthy SD male rats by adopting a compound factor method is characterized by comprising the following steps: the method comprises the following steps:
s1: culture of blood Stem cells
Adding PBS into intestinal blood for dilution, adding 10ml of lymphocyte separation liquid into a 50ml centrifuge tube, slowly adding the diluted intestinal blood, slowly sucking out the white cloudy lymphocyte layer in the middle of layering, adding PBS, centrifuging for 5 minutes, removing supernatant after centrifuging, adding fetal calf serum again, mixing uniformly, and repeatedly centrifuging once; discarding the supernatant, adding culture medium, mixing, and standing at 100cm2Culturing in the culture bottle;
s2: preparation of Stem cell active
Taking cultured stem cells for digestion and counting, washing fetal calf serum for 3 times, dissolving in 30ml of physiological saline, and ultrasonically breaking the cells; dissolving out intracellular protein and nutrients, centrifuging for 10 min, collecting supernatant, removing cell debris, concentrating with ultrafiltration membrane, removing immunoglobulin, collecting filtrate, filtering with filter membrane to obtain sterile solution with concentration of 200 μ g/ml, and storing at 4 deg.C to obtain solution A;
measuring the pH value of the upper layer culture solution of 30ml when the pH value of the culture medium for culturing the cells is 5.5, filtering by using a filter membrane to concentrate the volume of the upper layer culture solution to about 5ml, taking out the upper layer culture solution, adding 5ml of normal saline, and fixing the volume to 10 ml; filtering with 0.22 μm filter membrane to make it sterile, measuring protein concentration, determining concentration to be 200 μ g/ml, and storing at 4 deg.C to obtain solution B;
according to the following steps: 1: 1, mixing A, B with blood cells of schistosome to obtain active substance of blood stem cells;
s3: feeding and culturing adult SD male rats;
s4: feeding the rats after the weight measurement for 1 week, feeding high-fat CDAA feed, injecting blood stem cell active substances, continuously culturing for 8 weeks, wherein the injection of the blood stem cell active substances is carried out for 2 days in one week, and the common drinking water is carried out for the other 5 days;
s5: observing the mental state and hair condition of the rat every day during feeding, measuring the food intake and water intake, measuring the body weight of the rat every week, starting from the first feeding of high-fat CDAA diet and injection of blood stem cell active substances, continuously feeding for 8 weeks, and obtaining the rat with hepatic fibrosis.
2. The method for establishing hepatic fibrosis of healthy SD male rats by using the compound factor method according to claim 1, wherein the method comprises the following steps: s3 also comprises placing SD male rat in cage with room temperature of 25-30 deg.C and humidity of 55% -65%, adaptively feeding for 1 week in 12 hr light/dark cycle, and measuring weight of rat.
3. The method for establishing hepatic fibrosis of healthy SD male rats by using the compound factor method according to claim 2, wherein the method comprises the following steps: a high fat CDAA feed in S4, wherein, by weight: fat 32%, carbohydrate 55%, protein 13%, choline 0; the carbohydrate is starch, dextrin, sugar, and protein as amino acid premix, the fat is oleum Maydis and hydrogenated vegetable oil, and the calorie is 4.3 kcal/g.
4. The method for establishing hepatic fibrosis of healthy SD male rats by using the compound factor method according to claim 1, wherein the method comprises the following steps: the step of S1 further includes:
s11: when the cells grow to 80-90% of the bottom of the culture bottle, sucking out the culture medium, adding PBS for washing, sucking out PBS, adding pancreatin, adding alpha-MEM culture medium containing 20% fetal calf serum, neutralizing the pancreatin, sucking out the neutralization solution, putting into a centrifuge tube, adding PBS, centrifuging for 5 minutes, removing the supernatant after centrifugation, adding PBS, mixing uniformly, re-centrifuging once, counting the cells, adding 2X 105 cells into each bottle, and placing into a culture bottle of 100cm2 for culture.
5. The method for establishing hepatic fibrosis of healthy SD male rats by using the compound factor method according to claim 1, wherein the method comprises the following steps: further comprising S5:
the liver puncture tissue specimen of the SD male rat is directly provided with collagen specificity excitation spectrum to directly excite isolated liver tissue without any chemical special staining, and the inherent fluorescence characteristics of the liver tissue are observed by using a special fluorescence excitation block system of a fluorescence microscope to diagnose the liver fibrosis degree.
6. The method for establishing hepatic fibrosis of healthy SD male rats by using the compound factor method according to claim 5, wherein the method comprises the following steps: the excitation light wavelength of the special fluorescence excitation block in S5 is distributed in the lower range of 300nm-460nm, and the liver tissue section for liver fibrosis diagnosis is a liver tissue section without any staining.
7. The method for establishing hepatic fibrosis of healthy SD male rats by using the compound factor method according to claim 6, wherein the method comprises the following steps: the liver fibrosis diagnosis system aims at liver tissue sections including frozen sections and paraffin-embedded sections, and the inherent fluorescence of the liver tissue is generated after an optical filter in a lower wavelength range of 300nm-460nm or the excitation light of other corresponding light sources is excited without any chemical staining or fluorescence labeling.
8. The method for establishing hepatic fibrosis of healthy SD male rats by using the compound factor method according to claim 1, wherein the method comprises the following steps: the liver fibrosis diagnosis system of S5 comprises any means for determining the degree of liver fibrosis by means of the inherent fluorescence characteristics of the liver tissue specimen and the wavelength range of 300nm-460 nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011606455.XA CN112616775B (en) | 2020-12-30 | 2020-12-30 | Method for establishing hepatic fibrosis of healthy SD male rat by adopting compound factor method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011606455.XA CN112616775B (en) | 2020-12-30 | 2020-12-30 | Method for establishing hepatic fibrosis of healthy SD male rat by adopting compound factor method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112616775A true CN112616775A (en) | 2021-04-09 |
| CN112616775B CN112616775B (en) | 2023-02-10 |
Family
ID=75286502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011606455.XA Active CN112616775B (en) | 2020-12-30 | 2020-12-30 | Method for establishing hepatic fibrosis of healthy SD male rat by adopting compound factor method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112616775B (en) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101247829A (en) * | 2005-05-18 | 2008-08-20 | 生物基因Idec公司 | Methods for treating fibrotic conditions |
| CN101851605A (en) * | 2010-04-29 | 2010-10-06 | 北京弘润天源生物技术有限公司 | Selective medium of liver stem cells, method for selectively separating and amplifying liver stem cells as well as medicinal composition for treating diabetes |
| CN102758000A (en) * | 2011-04-29 | 2012-10-31 | 中国科学院上海生命科学研究院 | Organism lifetime based method for screening compounds capable of improving generation efficiency of induced pluripotent stem cells |
| CN102972345A (en) * | 2012-12-12 | 2013-03-20 | 贵州大学 | Modeling processing method of non-alcoholic fatty liver mouse model |
| CN105052830A (en) * | 2015-08-04 | 2015-11-18 | 施军平 | Fatty-liver-related liver cancer model building method based on knockout mice |
| CN106857406A (en) * | 2017-04-25 | 2017-06-20 | 遵义医学院 | A kind of method for building up by diet induced SD rat diabetes animal models |
| CN106946821A (en) * | 2017-04-01 | 2017-07-14 | 郑州大学 | The application of andrographolidume derivative and its 3,19 carboxylates in anti-hepatic fibrosis medicines are prepared |
| CN109136273A (en) * | 2017-06-16 | 2019-01-04 | 中国科学院上海生命科学研究院 | Prepare the method and its application of the rat of immune deficiency |
| CN109337860A (en) * | 2018-10-29 | 2019-02-15 | 妙顺（上海）生物科技有限公司 | A kind of hepatic fibrosis in vitro 3D model building method |
| CN109997787A (en) * | 2019-05-24 | 2019-07-12 | 河南中医药大学 | A kind of rat breeding method that nonalcoholic fatty liver disease is converted to hepatocellular carcinoma and application |
| CN110946877A (en) * | 2019-12-30 | 2020-04-03 | 深圳爱生再生医学科技有限公司 | Stem cell biological product for treating liver cirrhosis and preparation method and application thereof |
| CN111281885A (en) * | 2020-02-17 | 2020-06-16 | 卡替（上海）生物技术股份有限公司 | Method for reversing liver fibrosis by applying stem cell therapy |
-
2020
- 2020-12-30 CN CN202011606455.XA patent/CN112616775B/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101247829A (en) * | 2005-05-18 | 2008-08-20 | 生物基因Idec公司 | Methods for treating fibrotic conditions |
| CN101851605A (en) * | 2010-04-29 | 2010-10-06 | 北京弘润天源生物技术有限公司 | Selective medium of liver stem cells, method for selectively separating and amplifying liver stem cells as well as medicinal composition for treating diabetes |
| CN102758000A (en) * | 2011-04-29 | 2012-10-31 | 中国科学院上海生命科学研究院 | Organism lifetime based method for screening compounds capable of improving generation efficiency of induced pluripotent stem cells |
| CN102972345A (en) * | 2012-12-12 | 2013-03-20 | 贵州大学 | Modeling processing method of non-alcoholic fatty liver mouse model |
| CN105052830A (en) * | 2015-08-04 | 2015-11-18 | 施军平 | Fatty-liver-related liver cancer model building method based on knockout mice |
| CN106946821A (en) * | 2017-04-01 | 2017-07-14 | 郑州大学 | The application of andrographolidume derivative and its 3,19 carboxylates in anti-hepatic fibrosis medicines are prepared |
| CN106857406A (en) * | 2017-04-25 | 2017-06-20 | 遵义医学院 | A kind of method for building up by diet induced SD rat diabetes animal models |
| CN109136273A (en) * | 2017-06-16 | 2019-01-04 | 中国科学院上海生命科学研究院 | Prepare the method and its application of the rat of immune deficiency |
| CN109337860A (en) * | 2018-10-29 | 2019-02-15 | 妙顺（上海）生物科技有限公司 | A kind of hepatic fibrosis in vitro 3D model building method |
| CN109997787A (en) * | 2019-05-24 | 2019-07-12 | 河南中医药大学 | A kind of rat breeding method that nonalcoholic fatty liver disease is converted to hepatocellular carcinoma and application |
| CN110946877A (en) * | 2019-12-30 | 2020-04-03 | 深圳爱生再生医学科技有限公司 | Stem cell biological product for treating liver cirrhosis and preparation method and application thereof |
| CN111281885A (en) * | 2020-02-17 | 2020-06-16 | 卡替（上海）生物技术股份有限公司 | Method for reversing liver fibrosis by applying stem cell therapy |
Non-Patent Citations (2)
| Title |
|---|
| 梁丽清，苏华珍，陈少锋: ""肝纤维化动物模型研究进展"", 《广西中医药大学学报》 * |
| 色音图，于洪玲，闫国珍，杨静平: ""复合因子法建立大鼠肝纤维化模型的实验研究"", 《中国社区医师（综合版）》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112616775B (en) | 2023-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104164468B (en) | Method for preparing collagen peptide from animal cardiac tube | |
| CN105950564B (en) | The scorching virus of foreign duck liver and the method for preparing the scorching viral refined vitelline antibody of foreign duck liver using the virus | |
| CN110251671A (en) | Goose astrovirus Yolk antibody compound and preparation method thereof | |
| CN106581067A (en) | Pharmaceutical compositions and topical use thereof | |
| CN104745526B (en) | A kind of zebra fish primary embryonic cells vitro differentiation is the new method of cardiac muscle cell | |
| CN112616775B (en) | Method for establishing hepatic fibrosis of healthy SD male rat by adopting compound factor method | |
| CN101838626B (en) | Bartonella solid-liquid two-phase slant culture medium and preparation and application method thereof | |
| CN101481679A (en) | Fish egg cell extract and use thereof for inducing human adult cell to differentiate into pluripotent stem cell | |
| CN107557332A (en) | CD29+People's Mesenchymal Stem Cells from Umbilical Cord and its purposes in skeletal muscle atrophy medicine under preparing treatment high glucose and high fat environment | |
| CN106614426B (en) | A kind of angiostrongylus cantonensis in-vitro culture medium and extracorporeal culturing method | |
| CN106614158B (en) | A kind of Hementaria officianalis high-density breeding method | |
| CN102260728B (en) | Royal jelly polypeptide and application thereof | |
| CN116369249B (en) | Construction method of zebra fish enteritis model | |
| CN105457028B (en) | The stress sensitivity microRNA of regulating and controlling effect is played in bon e formation | |
| CN105586307A (en) | Separating method and culturing method for hepatic stellate cells of Mongolian gerbil | |
| CN109762062A (en) | A kind of preparation method of goose goat Yolk antibody | |
| Kusel et al. | The schistosome excretory system: a key to regulation of metabolism, drug excretion and host interaction | |
| CN106497871A (en) | A kind of method for improving human amnion mesenchymal stem cell Osteoblast Differentiation efficiency and application | |
| CN103555527B (en) | Snake peptide healthcare wine and preparation method thereof | |
| CN114557993A (en) | Application of 4-octyl itaconate in preparation of injection preparation before pancreas islet extraction | |
| Heath | The developmental biology of larval cyclophyllidean cestodes in mammals | |
| CN101548987B (en) | Cell culturing extract for degrading amyloid beta, preparation method and application thereof | |
| RU2815535C1 (en) | Method for increasing egg production of laying hens | |
| CN115976142A (en) | Method for preparing lipid-lowering oyster peptide by low-frequency ultrasonic field assisted enzymolysis | |
| CN102397534B (en) | Use of insulin in preparation of drug for promoting jaw bone tissue healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |